Skip to content
Master Your Financial Future — Master Your Money — Financial Insights Unveiled

Boston Scientific surges with record sales and bold acquisitions in 2025

A year of blockbuster deals and soaring profits. How Boston Scientific outpaced rivals with smart tech and relentless innovation.

,   and  Administrator
2 min read
The image shows a page from a book with a black and white image of a number line on it, which is a...
The image shows a page from a book with a black and white image of a number line on it, which is a patent for a method of calculating the number of people who have been diagnosed with cancer. The text and numbers on the page are likely related to the method, providing further details about the procedure.

Boston Scientific surges with record sales and bold acquisitions in 2025

Boston Scientific (BSX) has closed its latest acquisition while reporting strong financial results for 2025. The company finalised the purchase of Nalu and announced plans to acquire Valencia Technologies and Penumbra, broadening its reach in urology and cardiovascular markets. These moves come as BSX revealed record sales and earnings, surpassing its own growth targets for the year.

The company's fourth-quarter performance highlighted its momentum. Revenue hit $5.286 billion, with operational growth of 14.3% and organic growth of 12.7%. Adjusted earnings per share (EPS) rose 15% to $0.80, exceeding the guided range of $0.77 to $0.79. For the full year, BSX achieved $20.074 billion in sales, marking 19.2% operational growth and 15.8% organic growth.

Adjusted EPS for 2025 reached $3.06, a 22% increase that beat the company's forecast of $3.02 to $3.04. Operating margins also expanded by 100 basis points to 28%, reflecting improved efficiency. Looking ahead, BSX projects Q1 2026 adjusted EPS between $0.78 and $0.80, with full-year guidance of $3.43 to $3.49—representing 12% to 14% growth.

A key driver of success was the company's electrophysiology division. In Japan, its Farapulse product captured roughly 50% market share within two years of launch. This growth contrasted with competitors like Abbott and Johnson & Johnson, which saw international sales slow by around 600 basis points. BSX's strategy centred on minimally invasive procedures, advanced 3D-mapping systems, and precision ablation catheters, supported by targeted acquisitions to accelerate innovation.

Boston Scientific's acquisitions and financial performance position it strongly for 2026. The company expects organic growth of 8.5% to 10% in the first quarter and 10% to 11% for the full year. With expanded margins and a broader product portfolio, BSX continues to gain ground in key medical technology markets.

Read also:

Related

Latest